Association of SSRI and SNRI use with incidence of cardiovascular events in veterans with giant cell arteritis and polymyalgia rheumatica
The leading cause of death in patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) is cardiovascular disease. The objective of this study was to determine whether the use of selective serotonin reuptake inhibitors (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRI) in...
Saved in:
| Main Authors: | Tianyu Zhang, Chris A. Gentry, Nicole M. Kuderer, Gary H. Lyman, Bernard Ng, Despina Michailidou |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1509941/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Experience with olokizumab in the treatment of polymyalgia rheumatica and giant cell arteritis: A series of cases
by: Alexey D. Meshkov, et al.
Published: (2024-09-01) -
Pharmacotherapy of giant cell arteritis and polymyalgia rheumatica: Prospects for the use of monoclonal antibodies to interleukin 6
by: Evgeny L. Nasonov, et al.
Published: (2024-09-01) -
Baricitinib in polymyalgia rheumatica and giant cell arteritis: report of six cases
by: D. Camellino, et al.
Published: (2024-10-01) -
The evolution of diagnosis of polymyalgia rheumatica
by: A. M. Satybaldyev
Published: (2019-12-01) -
POLYMYALGIA RHEUMATICA
by: A. M. Satybaldyev, et al.
Published: (2018-05-01)